Report written content
Veteran biotech executive to head commercial partnerships to speed up drug discovery
SEATTLE — Parse Biosciences, a major supplier of accessible and scalable solitary mobile sequencing methods, right now declared that Julie Gerardi has joined the business as vice president of company growth. Gerardi will lead professional method for substantial scale purposes of Parse’s Evercode Entire Transcriptome, Evercode TCR, and CRISPR Detect platforms in pharmaceutical drug discovery and development.
Report content material
“As need increases for Parse’s single cell sequencing remedy in the drug discovery place, we have been bringing on talent that can support direct us via this next period of enlargement,” famous Parse CEO and co-founder Alex Rosenberg, Ph.D. “Julie has an inherent comprehension of this industry and the expertise and interactions to accelerate our presently appreciable expansion. We’re thrilled to have her be a part of us.”
A biochemist by education, Gerardi delivers far more than 25 a long time of expertise in the drug discovery field to this new job and has led industrial operations in little and massive scale organizations, from startups to Fortune 500 businesses. She joins Parse from Tempus Labs, the place she served as VP of business growth, overseeing professional operations and make up of their organic modeling and tumor organoid programs.
Beforehand, she was vice president of global sales and business operations – synthetic biology at Telesis Bio, and was also senior director of small business growth, strategic marketplaces spatial protein analysis – oncology at Definiens, in which she was a tactic partner in their integration into AstraZeneca. She examined biochemistry at the University of Tennessee, Knoxville and retains a diploma in biotechnology administration from Menlo School.
Famous Gerardi, “Evercode permits one cell following-era sequencing approaches to be utilized to tens of millions of cells from hundreds